Mohammad Mahdi Kooshyar1, Pegah Mosannen Mozafari2, Maryam Amirchaghmaghi2, Atessa Pakfetrat3, Parisa Karoos4, Mahdokht Rashed Mohasel5, Hosein Orafai6, Amir Abbas Azarian7. 1. Associate Professor, Department of Hematology and Oncology, Imam Reza Hospital, Mashhad University of Medicals, Mashhad, Khorasan Razavi, Iran. 2. Associate Professor, Department of Oral and Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran. 3. Professor, Department of Oral and Maxillofacial Diseases Research Center, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran. 4. General Dentist, Hojjati Dentistry Clinic, Mashhad, Khorasan Razavi, Iran. 5. Oral and Maxillofacial Medicine Specialist, Department of Pedodontics and Oral Medicine, North Khorasan University of Medical Sciences, Mashhad, Iran. 6. Professor, Department of Industrial Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Khorasan Razavi, Iran. 7. PhD Candidate of Statistics, Statistics Office, Mashhad University of Statistics, Mashhad, Iran.
Abstract
INTRODUCTION:Oral Mucositis (OM) is a serious complication of chemotherapy that results in painful debilitating inflammation that sometimes ends in interruption of treatment. AIM: The study evaluated the effect of quercetin (a natural flavonoid) on preventing and treating chemotherapy induced OM in patients with blood malignancies. Materials and Methods: This double-blind, placebo controlled randomized trial was carried out on 20 adult patients who underwent high dose chemotherapy for blood malignancies. Patients were divided into two groups (10 patients in the intervention group and 10 patients in the control group). Patients in the intervention group were administered 250 mg quercetin capsules twice daily for four weeks. RESULTS: Nine out of 20 patients developed OM (three in the intervention group and six in the control group). The incidence of OM was lower in the intervention group although it was not statistically significant (p=0.189). The mean severity of OM was higher in the intervention group (2.6 vs 2). Healing time, age, gender, type of malignancy, drug type and duration of OM were not different in two groups. CONCLUSION: The incidence of mucositis was lower in the quercetin group, but mucositis was more severe in the intervention group, which may be due to lower oral health status in the intervention group.
RCT Entities:
INTRODUCTION:Oral Mucositis (OM) is a serious complication of chemotherapy that results in painful debilitating inflammation that sometimes ends in interruption of treatment. AIM: The study evaluated the effect of quercetin (a natural flavonoid) on preventing and treating chemotherapy induced OM in patients with blood malignancies. Materials and Methods: This double-blind, placebo controlled randomized trial was carried out on 20 adult patients who underwent high dose chemotherapy for blood malignancies. Patients were divided into two groups (10 patients in the intervention group and 10 patients in the control group). Patients in the intervention group were administered 250 mg quercetin capsules twice daily for four weeks. RESULTS: Nine out of 20 patients developed OM (three in the intervention group and six in the control group). The incidence of OM was lower in the intervention group although it was not statistically significant (p=0.189). The mean severity of OM was higher in the intervention group (2.6 vs 2). Healing time, age, gender, type of malignancy, drug type and duration of OM were not different in two groups. CONCLUSION: The incidence of mucositis was lower in the quercetin group, but mucositis was more severe in the intervention group, which may be due to lower oral health status in the intervention group.
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2011-04-13
Authors: Helen V Worthington; Jan E Clarkson; Gemma Bryan; Susan Furness; Anne-Marie Glenny; Anne Littlewood; Martin G McCabe; Stefan Meyer; Tasneem Khalid Journal: Cochrane Database Syst Rev Date: 2010-12-08
Authors: Ana Teresa Azevedo Sachetto; Jackson Gabriel Miyamoto; Alexandre Keiji Tashima; Ana Olívia de Souza; Marcelo Larami Santoro Journal: Front Pharmacol Date: 2022-02-21 Impact factor: 5.810
Authors: Alexander T Sougiannis; Brandon N VanderVeen; J Mark Davis; Daping Fan; E Angela Murphy Journal: Am J Physiol Gastrointest Liver Physiol Date: 2021-01-20 Impact factor: 4.052